BioXcel Therapeutics (BTAI) Projected to Announce Earnings on Tuesday

BioXcel Therapeutics (NASDAQ:BTAI) is projected to issue its Q2 2026 results before the market opens on Tuesday, August 11th. Analysts expect the company to post earnings of ($0.44) per share and revenue of $0.4850 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Friday, August 14, 2026 at 9:30 AM ET.

BioXcel Therapeutics (NASDAQ:BTAI) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.53) by ($0.01). The business had revenue of $0.21 million for the quarter, compared to the consensus estimate of $0.38 million. On average, analysts expect BioXcel Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

BioXcel Therapeutics Stock Performance

Shares of NASDAQ:BTAI traded up $0.04 during trading on Tuesday, hitting $0.88. The company’s stock had a trading volume of 234,996 shares, compared to its average volume of 1,126,792. BioXcel Therapeutics has a fifty-two week low of $0.74 and a fifty-two week high of $8.08. The business has a 50 day moving average price of $1.08 and a two-hundred day moving average price of $1.30. The company has a market capitalization of $27.27 million, a PE ratio of -0.15 and a beta of 0.32.

Analyst Ratings Changes

A number of research firms recently issued reports on BTAI. Wall Street Zen lowered BioXcel Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioXcel Therapeutics in a research report on Friday, July 17th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, BioXcel Therapeutics has an average rating of “Hold” and an average target price of $11.00.

Institutional Trading of BioXcel Therapeutics

A number of large investors have recently made changes to their positions in the company. Goldman Sachs Group Inc. purchased a new position in BioXcel Therapeutics during the 1st quarter worth approximately $50,000. Geode Capital Management LLC lifted its stake in BioXcel Therapeutics by 27.7% in the second quarter. Geode Capital Management LLC now owns 28,182 shares of the company’s stock valued at $51,000 after buying an additional 6,120 shares during the last quarter. XTX Topco Ltd acquired a new stake in shares of BioXcel Therapeutics in the second quarter valued at approximately $42,000. Diversify Wealth Management LLC acquired a new stake in shares of BioXcel Therapeutics in the second quarter valued at approximately $27,000. Finally, Millennium Management LLC purchased a new position in shares of BioXcel Therapeutics during the third quarter worth approximately $2,632,000. 30.68% of the stock is owned by institutional investors and hedge funds.

BioXcel Therapeutics Company Profile

BioXcel Therapeutics, Inc is a biopharmaceutical company leveraging an AI-driven drug development platform to identify and advance novel or repurposed therapies in neuroscience and immunology. The proprietary BioXcel AI engine analyzes preclinical and clinical data to reveal new therapeutic applications for existing small molecules and biologics, aiming to streamline development timelines and improve patient outcomes.

BioXcel’s commercial portfolio includes two FDA-approved therapies. IGALMI® (dexmedetomidine) is indicated for the acute treatment of agitation in schizophrenia or bipolar I disorder, offering a noninvasive, sublingual delivery option.